GTx, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 94

GTx, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “GTx, Inc. - Product Pipeline Review - H2 2011” provides data on the GTx, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, GTx, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from GTx, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- GTx, Inc. - Brief GTx, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of GTx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of GTx, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the GTx, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of GTx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the GTx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with GTx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of GTx, Inc.; GTx, Inc. - Key Therapeutics; GTx, Inc. - Pipeline Overview and Promising Molecules; GTx, Inc. - News; GTx, Inc. - Latest Updates; GTx, Inc. - Pipeline; GTx, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
GTx, Inc. Snapshot
GTx, Inc. Overview
Key Information
Key Facts
GTx, Inc. – Research and Development Overview
Key Therapeutic Areas
GTx, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
GTx, Inc. – Pipeline Products Glance
GTx, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
GTx, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
GTx, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
GTx, Inc. – Drug Profiles
Acapodene
Product Description
Mechanism of Action
R&D Progress
Capesaris
Product Description
Mechanism of Action
R&D Progress
Gtx-186
Product Description
Mechanism of Action
R&D Progress
Gtx-230
Product Description
Mechanism of Action
R&D Progress
MK-0773
Product Description
Mechanism of Action
R&D Progress
GTx, Inc. – Pipeline Analysis
GTx, Inc. – Pipeline Products by Therapeutic Class
GTx, Inc. - Pipeline Products By Target
GTx, Inc. – Pipeline Products by Route of Administration
GTx, Inc. – Pipeline Products by Molecule Type
GTx, Inc. – Recent Pipeline Updates
GTx, Inc. - Dormant Projects
GTx, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Acapodene
GTx, Inc. – Company Statement
GTx, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Dec 30, 2008: GTx Submits New Drug Application for Toremifene 80 mg for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy
Dec 30, 2008: GTx Submits New Drug Application For Toremifene 80 mg For The Prevention Of Bone Fractures In Men With Prostate Cancer On Androgen Deprivation Therapy
Jun 30, 2011: GTx Announces Upcoming Presentations Of Effects Of Ostarine In Non-Small Cell Lung Cancer Patients At World Conference On Lung Cancer
Jul 28, 2008: GTx Announces Phase III Clinical Development Of Toremifene 20 mg On Course Following Planned Safety Review
May 28, 2010: GTx Announces Upcoming Presentation Of Additional Study Results From Phase III Clinical Trial Of Toremifene 80mg
May 28, 2009: GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data To Be Presented At The Annual Meeting Of The American Society Of Clinical Oncology
Apr 27, 2009: GTx Announces Phase III Results For Toremifene 80 mg
Feb 26, 2009: GTx Announces Phase III Clinical Development Of Toremifene 20 mg On Course Following Planned Safety Review
Feb 26, 2009: GTx Announces Phase III Clinical Development Of Toremifene 20 mg On Course Following Planned Safety Review
May 25, 2010: GTx Announces Top Line Results Of Phase III Clinical Trial Evaluating Toremifene 20mg For Prevention Of Prostate Cancer In Men With High Grade PIN
May 25, 2010: GTx Announces Top Line Results Of Phase III Clinical Trial Evaluating Toremifene 20mg For Prevention Of Prostate Cancer In Men With High Grade PIN
May 25, 2007: GTx Announces Presentation Of Ostarine And ACAPODENE Data At 2007 ASCO Annual Meeting
May 25, 2007: GTx Announces Presentation Of Ostarine And ACAPODENE Data At 2007 ASCO Annual Meeting
Feb 25, 2008: GTx's Toremifene Citrate 80 mg Meets Primary And Key Endpoints In Phase III Trial In Advanced Prostate Cancer Patients On Androgen Deprivation Therapy
Jun 23, 2003: GTx, Inc., Presents Preclinical Data On Its SARMS Program At The 85th Annual Meeting Of The Endocrine Society
May 23, 2008: GTx Announces Phase III PIN Clinical Trial Will Continue As Planned
Mar 23, 2010: GTx And Ipsen Expand Toremifene Partnership To Encompass FDA’s Requested 2nd Phase III Trial
Feb 23, 2009: GTx Initiates Phase I Clinical Trial Of GTx-758 For Prostate Cancer
Feb 23, 2007: GTx's ACAPODENE Interim Bone Mineral Density And Lipid Data Highlighted At Press Briefing At Prostate Cancer Symposium Of The American Society Of Clinical Oncology
Jan 23, 2009: GTx Announces Conference Call To Discuss EMEA Label Changes To Fareston
Apr 22, 2009: GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data To Be Presented At The Annual Meeting Of The American Urological Association
Feb 22, 1996: Fareston Receives EU Marketing Clearance for Advanced Breast Cancer
Jun 21, 2010: GTx Reports Ostarine Increased Lean Body Mass And Leg Press Strength In Head To Head Clinical Study
Feb 21, 2007: GTx Announces Presentation Of ACAPODENE Data At ASCO Prostate Cancer Symposium
Jul 20, 2006: GTx, Inc. Completes Enrollment Of Phase II Ostarine Trial
Jun 20, 2011: GTx Initiates Phase IIb Clinical Trial Evaluating Oral Capesaris Tablets Versus Lupron Depot For First Line Treatment Of Advanced Prostate Cancer
May 20, 2010: GTx To Present Additional Study Results From Clinical Trials Evaluating Toremifene 80mg For Reduction Of Fractures In Men With Prostate Cancer On ADT
May 18, 2011: GTx Announces ASCO Presentations Highlighting Effects Of Ostarine On Physical Function And Survival In Patients With Non-Small Cell Lung Cancer
Feb 18, 2009: GTx Announces Toremifene 80 mg NDA Accepted For Review By FDA
May 17, 2011: GTx Presents Preclinical Study Results Demonstrating Capesaris Chronic Treatment Does Not Cause Gynecomastia In Male Primates
Apr 17, 2007: GTx Announces Ostarine(TM) Improved Insulin Resistance Among Elderly Patients In A Recently Completed Phase II Clinical Trial
Sep 16, 2008: GTx Presents Bone Turnover Marker Data And Additional PSA Progression Safety Analysis For Toremifene 80 mg Phase III ADT Clinical Trial
Nov 15, 2010: GTx Presents Preclinical Studies GTx-230, An Orally Available Tubulin Antagonist For Cancer Refractory To Taxane And Vinca Alkaloid Therapy
Sep 15, 2010: GTx Reports Phase II Clinical Trial Results Of Gtx-758 For Treatment Of Advanced Prostate Cancer
May 15, 2006: GTx, Inc. Initiates Phase II Clinical Trial Of Ostarine ,A First-in-Class Drug
Apr 15, 2008: First Fracture Prevention Study In Men Receiving ADT For Prostate Cancer Presented At AACR Annual Meeting
Mar 15, 2005: GTx, Inc.'s Second SARM Shows Phase I Clinical Safety
Sep 14, 2009: GTx Announces Phase III Clinical Development Of Toremifene 20 mg On Course Following Planned Safety Review
Dec 13, 2010: GTx Reports Promising Results From Phase II Prostate Cancer Trial With GTx-758
Oct 13, 2008: GTx Announces Investigational Ostarine (MK-2866) Met The Primary Endpoint In The Phase II Cancer Cachexia Clinical Trial
Jul 12, 2007: GTx's Phase III Clinical Development Of ACAPODENE On Course Following Planned Safety Review
Jun 11, 2009: GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results At Endocrine Society Annual Meeting
Apr 11, 2007: GTx To Host An Analyst Day To Provide An Update On ACAPODENE Phase III Clinical Programs And Information On The Clinical Development And Commercialization Strategy For Ostarine
Apr 11, 2007: GTx To Host An Analyst Day To Provide An Update On ACAPODENE Phase III Clinical Programs And Information On The Clinical Development And Commercialization Strategy For Ostarine
Sep 08, 1999: Roberts Pharmaceutical Corporation and Orion Corporation Agree on U.S. Rights To Market Fareston, A Treatment for Advanced Breast Cancer
Jun 08, 2010: GTx Announces Toremifene 80mg Treatment Demonstrated Improved Fracture Reduction And Safety Profile In Men With Prostate Cancer On ADT Younger Than Age 80
Jun 08, 2009: GTx Announces Ostarine(TM) (MK-2866) Clinical Trial Data To Be Presented At ENDO 2009
Sep 07, 2005: GTx, Inc. Announces Positive Clinical Results And Development Plans For Ostarine
Jul 07, 2009: GTx Initiates The Second Phase I Clinical Trial Of GTx For Prostate Cancer
Jun 07, 2010: GTx Presents Additional Study Results From Phase IIb Clinical Trial Evaluating Ostarine For Cancer Induced Muscle Wasting
Jun 06, 2011: GTx Announces Agreement With FDA On Phase III Clinical Development Plan Of Ostarine For Treatment Of Muscle Wasting In Patients With NSCLC
Mar 05, 2009: FDA Provides PDUFA Target Agency Action Date For GTx's Toremifene 80 mg NDA
Jul 03, 2007: GTx Initiates Phase IIb Ostarine Clinical Trial For Cancer Cachexia
Mar 03, 2008: GTx Presents Additional Top Line Phase III Data Demonstrating Toremifene Citrate 80 mg Reduced Hot Flashes In Men With Prostate Cancer On Androgen Deprivation Therapy
Nov 02, 2009: GTx Receives Complete Response Letter From FDA For Toremifene 80 mg New Drug Application
Jun 02, 1997: FDA Clears Fareston as First-Line Treatment of Metastatic Breast Cancer
Feb 02, 2007: GTx's Phase III Clinical Development Of ACAPODENE On Course Following Planned Safety Review
Jun 01, 2009: GTx Presents Phase III Results For Toremifene 80 Mg
Feb 01, 2005: GTx, Inc. Initiates Phase I Clinical Trial For Its Second SARM Ostarine
Financial Deals Landscape
GTx, Inc., Deals Summary
GTx, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
GTx Acquires Rights To Toremifene From Orion
Partnerships
GTx Enters Into Co-Development Agreement With Tessera
GTx Enters Into Collaboration Agreement With diaDexus
Licensing Agreements
GTx Expands Its Collaboration With Ipsen
GTx Enters Into Licensing Agreement With Merck & Co.
Ipsen Enters Into Licensing Agreement With GTx
GTx Enters Into Worldwide Licensing Agreement With Ortho Biotech
Equity Offering
GTx Prices An Underwritten Public Offering Of $47.5 Million
GTx Completes Public Offering Of $40 Million
GTx Closes Private Placement Of $30 Million
GTx Completes Public Offering Of $61 Million
GTx Completes Public Offering Of $49 Million
GTx Completes Initial Public Offering Of $78 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
GTx, Inc. – Pipeline by Therapy Area and Indication, H2 2011
GTx, Inc. – Pipeline by Stage of Development, H2 2011
GTx, Inc. – Monotherapy Products in Pipeline, H2 2011
GTx, Inc. – Filed, H2 2011
GTx, Inc. - Phase II, H2 2011
GTx, Inc. - Phase I, H2 2011
GTx, Inc. - Pipeline By Therapeutic Class, H2 2011
GTx, Inc. - Pipeline By Target, H2 2011
GTx, Inc. – Pipeline By Route of Administration, H2 2011
GTx, Inc. – Pipeline By Molecule Type, H2 2011
GTx, Inc. – Recent Pipeline Updates, H2 2011
GTx, Inc. - Dormant Developmental Projects, 2010
GTx, Inc. - Discontinued Pipeline Products, 2010
GTx, Inc., Deals Summary
GTx Acquires Rights To Toremifene From Orion
GTx Enters Into Co-Development Agreement With Tessera
GTx Enters Into Collaboration Agreement With diaDexus
GTx Expands Its Collaboration With Ipsen
GTx Enters Into Licensing Agreement With Merck & Co.
Ipsen Enters Into Licensing Agreement With GTx
GTx Enters Into Worldwide Licensing Agreement With Ortho Biotech
GTx Prices An Underwritten Public Offering Of $47.5 Million
GTx Completes Public Offering Of $40 Million
GTx Closes Private Placement Of $30 Million
GTx Completes Public Offering Of $61 Million
GTx Completes Public Offering Of $49 Million
GTx Completes Initial Public Offering Of $78 Million

List of Figures
GTx, Inc. – Pipeline by Therapy Area and Indication, H2 2011
GTx, Inc. – Pipeline by Stage of Development, H2 2011
GTx, Inc. – Monotherapy Products in Pipeline, H2 2011
GTx, Inc. – Pipeline By Therapeutic Class, H2 2011
GTx, Inc. - Pipeline By Target, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• United Parcel Service - IT Sales Opportunities - 2009
• Insight into Samsung Electronics' Notebook PC Business Model